Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
Conditions: Dengue; Vector Borne Diseases; Arbovirus Infections; Zika; Chikungunya Fever Interventions: Other: Insecticide Coating INESFLY Sponsors: Rocio Cardenas Sanchez; G öteborg University; Instituto Nacional de Salud, Colombia; Instituto Departamental de Salud de Norte de Santander; Universidad Francisco de Paula de Santander Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
Conditions: Dengue; Chikungunya; Malaria Interventions: Diagnostic Test: VIDAS ® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG; Other: Standard of care practices Sponsors: BioM érieux Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Oral Ivermectin for Chikungunya Viral Infection
Conditions: Clinical Syndrome Interventions: Drug: Ivermectin Sponsors: Prince of Songkla University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
A Dose Response Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years
Conditions: Chikungunya Virus Infection Interventions: Biological: VLA1553 full dose; Biological: VLA1553 half dose; Biological: Control Sponsors: Valneva Austria GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate
Saint-Herblain (France), August 14, 2023– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has revised the Prescription Drug User Fee Act (PDUFA)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 14, 2023 Category: Pharmaceuticals Source Type: clinical trials
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
Saint-Herblain (France), June 13, 2023– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that the Company’s pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
Saint Herblain (France), May 25, 2022– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 25, 2022 Category: Pharmaceuticals Source Type: clinical trials
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
Condition: Chikungunya Virus Interventions: Biological: CHIKV VLP/adjuvant; Biological: Placebo Sponsors: Emergent BioSolutions; Catalyst Clinical Research Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2022 Category: Research Source Type: clinical trials
